Edwards Lifesciences Corp EW

Edwards Lifesciences Corporation es un fabricante de sistemas de válvulas cardíacas y productos de reparación utilizados para reemplazar o reparar la válvula cardíaca enferma o defectuosa de un paciente. Los productos y tecnologías de la empresa se dividen en cuatro áreas principales: Reemplazo de Válvula Aórtica Transcatéter, Terapias Mitral y Tricúspide Transcatéter, Corazón Estructural Quirúrgico y Cuidados Críticos. También desarrolla sistemas de monitoreo hemodinámico y de oxigenación cerebral y tisular no invasivos que se utilizan para medir la función cardiovascular de un paciente en el entorno hospitalario. La familia de válvulas Edwards SAPIEN, incluidas las válvulas cardíacas aórticas transcaterter Edwards SAPIEN XT, Edwards SAPIEN 3 y Edwards SAPIEN 3 Ultra, se utilizan para tratar enfermedades de las válvulas cardíacas. Opera a nivel mundial y tiene presencia en diversas regiones geográficas, incluidos Estados Unidos, Europa, Japón y el Resto del Mundo. Vende productos que se utilizan para tratar enfermedades cardiovasculares avanzadas en todas las regiones.

EW hizo una división de acciones (split) de 3:1 el 1 de junio de 2020: cada acción se convirtió en 3. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 1 sept

  Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?

  Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.

  

• GlobeNewswire Inc. 9 jul

  TRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement System

  TRiCares has enrolled the first patient in its TRICURE US IDE pivotal study for the Topaz tricuspid valve replacement system, marking the first randomized controlled trial comparing an investigational TTVR device against Edwards' commercially available EVOQUE system. The global study will involve up to 75 sites across the US, Canada, and Europe, with the goal of demonstrating safety and effectiveness for treating severe tricuspid regurgitation.

  

• Benzinga 16 jun

  Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device

  The Centers for Medicare & Medicaid Services (CMS) proposed removing coverage with evidence development (CED) requirements for Transcatheter Aortic Valve Replacement (TAVR) in symptomatic severe aortic stenosis patients and expanding coverage to asymptomatic cases under CED. Edwards Lifesciences, which holds the only FDA-approved TAVR device for asymptomatic severe aortic stenosis, stands to gain a competitive advantage from these proposed changes. The stock rose 3.74% to $88.65 following the announcement.